First study of HH160 in adults with advanced solid tumors
Tests the safety of HH160, alone or combined, in advanced solid tumors.
Plain-language title generated from the registry record
Registry title: A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
Key facts
- Where
- Jinan, ChinaSee the site
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07623369, who can take part
Where in China
- Shandong Tumour Hospital Dongyuan UnitJinan, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Huahui Health
- Trial code
- NCT07623369
- Record updated
- 21 August 2026
- Original description
This study is evaluating the safety, side effects, how the body processes HH160, and its early anticancer activity when given alone or with other cancer treatments in participants with advanced solid tumors. The study will also identify the recommended dose for future studies. The trial includes two phases and is expected to last about 4 years, with treatment and follow-up lasting approximately 6-12 months each.Read full original descriptionShow less
An Open-Label, Multicenter, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Preliminary Antitumor Activity of HH160 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors
This study is evaluating the safety, side effects, how the body processes HH160, and its early anticancer activity when given alone or with other cancer treatments in participants with advanced solid tumors. The study will also identify the recommended dose for future studies. The trial includes two phases and is expected to last about 4 years, with treatment and follow-up lasting approximately 6-12 months each.
Inclusion: Adults aged 18 to 75 years with signed informed consent; Histologically or cytologically confirmed advanced solid tumors meeting phase-specific disease requirements; At least 1 measurable lesion per RECIST v1.1; Eastern Cooperative Oncology Group Performance Status (ECOG) Performance Status of 0 or 1 with life expectancy ≥ 12 weeks; Adequate organ function based on protocol-specified laboratory criteria.
Exclusion: Other malignancy within 3 years prior to first dose, except specified curatively treated cancers; Active leptomeningeal disease or uncontrolled/untreated brain metastases; History of severe hypersensitivity reactions to monoclonal antibodies, bispecific antibodies, trispecific antibodies, or study drug components; Significant bleeding risk, severe coagulopathy, gastrointestinal hemorrhage, or recent pulmonary hemorrhage/hemoptysis; NOTE: Other eligibility criteria may apply; Uncontrolled pleural effusion, pericardial effusion, or ascites requiring frequent drainage.